-       Report 
   - October 2025
    -  193 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  198 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  188 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                 -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - November 2025
    -  193 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  194 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Report 
   - October 2025
    -  194 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - May 2025
    -  114 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - May 2025
    -  110 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - September 2025
    -  149 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                -       Report 
   - March 2025
    -  191 Pages 
    Global
   
   From       €2247EUR$2,500USD£1,971GBP 
                -       Report 
   - July 2025
    -  350 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - May 2025
    -  93 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                  -       Report 
   - August 2025
    -  150 Pages 
    Global
   
   From       €3018EUR$3,358USD£2,647GBP 
      €3550EUR$3,950USD£3,114GBP 
                  -       Report 
   - September 2025
    -  135 Pages 
    Global
   
   From       €3705EUR$4,123USD£3,250GBP 
      €4359EUR$4,850USD£3,823GBP 
                -       Report 
   - January 2025
    -  210 Pages 
    Global
   
   From       €4490EUR$4,995USD£3,937GBP 
             
         Isoflurane is an anesthetic drug used in medical procedures to induce and maintain general anesthesia. It is a volatile anesthetic, meaning it is administered as a gas and is rapidly eliminated from the body. Isoflurane is a halogenated ether, meaning it contains a halogen atom, such as fluorine, attached to an ether molecule. It is a colorless, nonflammable gas with a sweet odor and is used in a variety of medical procedures, including surgery, endoscopy, and diagnostic imaging.
Isoflurane is one    of the most commonly used anesthetic drugs in the world. It is considered to be a safe and effective anesthetic, with few side effects. It is also relatively inexpensive compared to other anesthetic drugs. Isoflurane is used in both adults and children, and is often used in combination with other anesthetic drugs.
Some of the companies in the isoflurane market include Baxter International, Hospira, Inc., Merck & Co., Inc., and AbbVie, Inc. Show Less   Read more